Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in:

Open Access 01-12-2024 | Systematic Review

Comparing cognitive impairment using MACFIMS in patients with multiple sclerosis and healthy controls: a systematic review and meta-analysis

Authors: Amirreza Nasirzadeh, Mohammad Mohammadi, Melika Arab Bafrani, Aynaz Mohammadi, Hossein Bakhtiari-Dovvombaygi

Published in: BMC Neurology | Issue 1/2024

Login to get access

Abstract

Background

Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, leading to a range of symptoms that impact physical, psychiatric, and cognitive functions. Cognitive dysfunction is prevalent among patients with MS (pwMS), affecting at least 65% of patients, and includes deficits in processing speed, attention, learning, memory, and executive function. Despite the significant impact on daily life, cognitive impairment in MS patients is often underrecognized in clinical settings.

Methods

This systematic review and meta-analysis aimed to evaluate cognitive function using the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery among pwMS patients and healthy controls (HCs). A comprehensive search of the Web of Science, PubMed, Scopus, and Cochrane Library databases was conducted on January 2024 following the PRISMA guidelines. Eligible studies included peer-reviewed research assessing the validity of the MACFIMS in adult MS patients. Data extraction and quality assessment were performed using standardized tools, and statistical analyses were conducted using R4.2.3.

Results

Eight studies met the inclusion criteria, including a total of 1,481 pwMS and 1,072 HCs. The meta-analysis revealed significant cognitive deficits in pwMS patients compared to HCs across all the MACFIMS subtests, including language, spatial processing, new learning and memory, processing speed, and executive function. Processing speed and working memory were the most affected domains, with 36% of pwMS showing impairment on the Symbol Digit Modalities Test (SDMT). Subgroup analyses indicated that the Expanded Disability Status Scale (EDSS) score significantly influenced cognitive impairment, while disease duration had a limited impact.

Conclusions

The MACFIMS effectively discriminates between pwMS patients and HCs, demonstrating its validity as a comprehensive cognitive assessment tool for MS. Routine cognitive screening, particularly for processing speed and working memory, is crucial for early detection and intervention. Future research should focus on the sensitivity and specificity of the MACFIMS across diverse MS subtypes and cultural contexts to enhance its global applicability in clinical practice.
Appendix
Available only for authorised users
Literature
1.
2.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.PubMedPubMedCentralCrossRef
3.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.PubMedCrossRef
4.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Author correction: multiple sclerosis. Nat Reviews Disease Primers. 2018;4(1):49.CrossRef
5.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Multiple Scler J. 2020;26(14):1816–21.CrossRef
6.
Habbestad A, Willumsen JS, Aarseth JH, Grytten N, Midgard R, Wergeland S, et al. Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. J Neurol. 2024;271(4):1610–7.PubMedCrossRef
7.
Jellinger KA. Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms. J Neural Transm. 2024;131(8):871–99.PubMedCrossRef
8.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol. 2019;10:581.PubMedPubMedCentralCrossRef
9.
Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278–88.PubMedPubMedCentralCrossRef
10.
DeLuca J, Chiaravalloti ND, Sandroff BM. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Reviews Neurol. 2020;16(6):319–32.CrossRef
11.
Sehanovic A, Smajlovic D, Tupkovic E, Ibrahimagic OC, Kunic S, Dostovic Z, et al. Cognitive disorders in patients with multiple sclerosis. Materia socio-medica. 2020;32(3):191.PubMedPubMedCentralCrossRef
12.
Longley WA, Honan C. Cognitive impairment in multiple sclerosis: the role of the general practitioner in cognitive screening and care coordination. Australian J Gen Pract. 2022;51(4):225–31.CrossRef
13.
14.
15.
Romero K, Shammi P, Feinstein A. Neurologists׳ accuracy in predicting cognitive impairment in multiple sclerosis. Multiple Scler Relat Disorders. 2015;4(4):291–5.CrossRef
16.
Elwick H, Smith L, Mhizha-Murira JR, Topcu G, Leighton P, Drummond A, et al. Cognitive assessment in multiple sclerosis clinical care: a qualitative evaluation of stakeholder perceptions and preferences. Neuropsychological Rehabilitation. 2022;32(7):1456–74.PubMedCrossRef
17.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Scler J. 2018;24(13):1665–80.CrossRef
18.
Klein OA, Das Nair R, Ablewhite J, Drummond A. Assessment and management of cognitive problems in people with multiple sclerosis: a National Survey of Clinical Practice. Int J Clin Pract. 2019;73(3):e13300.CrossRef
19.
Potticary H, Langdon D. A systematic review and meta-analysis of the brief cognitive assessment for multiple sclerosis (BICAMS) international validations. J Clin Med. 2023;12(2):703.PubMedPubMedCentralCrossRef
20.
Meca-Lallana V, Gascón-Giménez F, Ginestal-López RC, Higueras Y, Téllez-Lara N, Carreres-Polo J et al. Cognitive impairment in multiple sclerosis: diagnosis and monitoring. Neurol Sci. 2021:1–11.
21.
Thrue C, Riemenschneider M, Hvid L, Stenager E, Dalgas U. Time matters: early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains. Multiple Scler J. 2021;27(10):1477–85.CrossRef
22.
Langdon D. Fast facts: cognition in multiple sclerosis. 2023.
23.
Langdon D, Amato M, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Multiple Scler J. 2012;18(6):891–8.CrossRef
24.
Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12(4):549–58.PubMedCrossRef
25.
Smith A. Symbol digit modalities test. The clinical neuropsychologist. 1973.
26.
Benedict RHB, Zivadinov R. Reliability and validity of neuropsychological screening and assessment strategies in MS. J Neurol. 2007;254(2):II22–5.PubMed
27.
Elwood RW. The California Verbal Learning Test: psychometric characteristics and clinical application. Neuropsychol Rev. 1995;5:173–201.PubMedCrossRef
28.
Barr W, Morrison C, Zaroff C, Devinsky O. Use of the brief Visuospatial Memory Test—revised (BVMT-R) in neuropsychological evaluation of epilepsy surgery candidates. Epilepsy Behav. 2004;5(2):175–9.PubMedCrossRef
29.
Benedict RH, Schretlen D, Groninger L, Dobraski M, Shpritz B. Revision of the brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol Assess. 1996;8(2):145.CrossRef
30.
Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. Assessment. 2001.
31.
Ruff R, Light R, Parker S, Levin H. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329–38.PubMedCrossRef
32.
Benton AL, Varney N. Hamsher Kd. Judgment of line orientation. 1983.
33.
Tranel D, Vianna E, Manzel K, Damasio H, Grabowski T. Neuroanatomical correlates of the Benton facial recognition test and judgment of line orientation test. J Clin Exp Neuropsychol. 2009;31(2):219–33.PubMedPubMedCentralCrossRef
34.
Benedict R, Amato M, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. MULTIPLE Scler J. 2011;17:S397–8.
35.
Feinstein A, Lapshin H, O’Connor P. Looking anew at cognitive dysfunction in multiple sclerosis: the gorilla in the room. Neurology. 2012;79(11):1124–9.PubMedPubMedCentralCrossRef
36.
Maubeuge N, Deloire MS, Brochet B, Ehrlé N, Charré-Morin J, Saubusse A, et al. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Multiple Scler Relat Disorders. 2021;48:102692.CrossRef
37.
Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS). Clin Neuropsychol. 2012;26(7):1186–200.PubMedCrossRef
38.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group* t. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.PubMedCrossRef
39.
Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The mixed methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Educ Inform. 2018;34(4):285–91.CrossRef
40.
Argento O, Incerti CC, Quartuccio ME, Magistrale G, Francia A, Caltagirone C, et al. The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the cognitive impairment index scoring procedure in MS patients. Neurol Sci. 2018;39(7):1237–44.PubMedCrossRef
41.
Berard JA, Walker LAS. Validity and sensitivity of Canadian normative data for the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) battery. Mult Scler Relat Disord. 2022;63:103865.PubMedCrossRef
42.
Eshaghi A, Riyahi-Alam S, Roostaei T, Haeri G, Aghsaei A, Aidi MR, et al. Validity and reliability of a persian translation of the Minimal Assessment of cognitive function in multiple sclerosis (MACFIMS). Clin Neuropsychol. 2012;26(6):975–84.PubMedCrossRef
43.
Maubeuge N, Deloire MSA, Brochet B, Ehrlé N, Charré-Morin J, Saubusse A, et al. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Mult Scler Relat Disord. 2021;48:102692.PubMedCrossRef
44.
Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Landi D, Palmieri MG, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population. Neurol Sci. 2016;37(8):1261–70.PubMedCrossRef
45.
Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, et al. Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behav Neurol. 2017;2017:7404289.PubMedPubMedCentralCrossRef
46.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–79.PubMedCrossRef
47.
Johnen A, Landmeyer NC, Bürkner P-C, Wiendl H, Meuth SG, Holling H. Distinct cognitive impairments in different disease courses of multiple sclerosis—A systematic review and meta-analysis. Neurosci Biobehavioral Reviews. 2017;83:568–78.CrossRef
48.
Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, et al. Validity of the Symbol Digit modalities Test as a cognition performance outcome measure for multiple sclerosis. Multiple Scler J. 2017;23(5):721–33.CrossRef
49.
Grothe M, Jochem K, Strauss S, Langner S, Kirsch M, Hoffeld K, et al. Performance in information processing speed is associated with parietal white matter tract integrity in multiple sclerosis. Front Neurol. 2022;13:982964.PubMedPubMedCentralCrossRef
50.
Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict R. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao brief repeatable neuropsychological battery and the Minimal Assessment of cognitive function in MS. Multiple Scler J. 2009;15(9):1077–84.CrossRef
51.
Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner I-K, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015;14(3):302–17.PubMedCrossRef
52.
Goverover Y, Chiaravalloti ND, O’Brien AR, DeLuca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: an updated review of the literature from 2007 to 2016. Arch Phys Med Rehabil. 2018;99(2):390–407.PubMedCrossRef
53.
Chiaravalloti ND, Moore NB, Weber E, DeLuca J. The application of strategy-based Training to enhance memory (STEM) in multiple sclerosis: a pilot RCT. Neuropsychological Rehabilitation. 2021;31(2):231–54.PubMedCrossRef
54.
Mousavi S, Zare H, Etemadifar M. Evaluating the effectiveness of cognitive rehabilitation on everyday memory in multiple sclerosis patients. Neuropsychological Rehabilitation. 2018.
55.
Ruet A, Brochet B. Cognitive assessment in patients with multiple sclerosis: from neuropsychological batteries to ecological tools. Annals Phys Rehabilitation Med. 2020;63(2):154–8.CrossRef
56.
Glukhovsky L, Brandstadter R, Leavitt VM, Krieger S, Buyukturkoglu K, Fabian M, et al. Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. Multiple Scler J. 2021;27(4):568–78.CrossRef
57.
van Dam M, Krijnen EA, Nauta IM, Fuchs TA, de Jong BA, Klein M et al. Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning. J Neurol. 2024:1–12.
58.
Sumowski JF, Rocca MA, Leavitt VM, Riccitelli G, Comi G, DeLuca J, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology. 2013;80(24):2186–93.PubMedPubMedCentralCrossRef
59.
Chen MH, Chiaravalloti ND, DeLuca J. Neurological update: cognitive rehabilitation in multiple sclerosis. J Neurol. 2021;268(12):4908–14.PubMedCrossRef
60.
Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721–33.PubMedPubMedCentralCrossRef
61.
Calocer F, Ng HS, Zhu F, Zhao Y, Dejardin O, Leray E, et al. Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis. Multiple Scler J. 2023;29(3):466–70.CrossRef
62.
Towfighi A, Berger RP, Corley AM, Glymour MM, Manly JJ, Skolarus LE. Recommendations on social determinants of health in neurologic disease. Neurology. 2023;101(7Supplement1):S17–26.PubMed
Metadata
Title
Comparing cognitive impairment using MACFIMS in patients with multiple sclerosis and healthy controls: a systematic review and meta-analysis
Authors
Amirreza Nasirzadeh
Mohammad Mohammadi
Melika Arab Bafrani
Aynaz Mohammadi
Hossein Bakhtiari-Dovvombaygi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-024-03943-2

Other articles of this Issue 1/2024

Autoimmune encephalitis with coexisting antibodies to GABABR, GAD65, SOX1 and Ma2

  • Open Access
  • Case Report

Convexity subarachnoid hemorrhage revealed contralateral internal carotid artery dissection due to Eagle syndrome: a case report

Re-irradiation for recurrent glioblastoma: a pattern of care analysis

  • Open Access
  • Research

A patient with P369S/R408Q variants in the MEFV gene presented with clinical features of Kikuchi disease and Mollaret meningitis, successfully treated with colchicine

  • Open Access
  • Case Report

Severe CSF immune cell alterations in cryptococcal meningitis gradually resolve during antifungal therapy

The relationship between micronutrients and cognitive ability in an elderly population with mild cognitive impairment and Alzheimer’s disease: a cross-sectional study